

2 March 2016

Leading Paediatric Oncologist Dr Noah Federman Joins Zelda Therapeutics' Scientific Advisory Board

Highlights

- Distinguished oncologist and physician scientist, Dr Noah Federman, has joined Zelda's Scientific Advisory Board
- Dr Federman holds extensive clinical oncology experience specialising in treating children with aggressive cancers
- His knowledge and experience in the oncology field will be highly valuable for developing rigorous medical cannabis clinical trials in cancer
- Dr Federman joins an established and well credentialed Scientific Advisory Board and follows the recent appointment of leading clinician Dr Joe Goldstrich
- His appointment signals the strong level of medical and scientific support for Zelda's strategy to validate the efficacy of medical cannabis in key indications

Gleneagle Gold Limited (ASX:GLN) is pleased to provide an update on behalf of Zelda Therapeutics Pty Ltd ("Zelda"). Zelda has appointed distinguished paediatric oncologist Dr Noah Federman, to the Company's Scientific Advisory Board with immediate effect.

His appointment follows the recent appointment of leading US clinician Dr Joe Goldstrich, in February 2016 and signals the strong level of medical and scientific support for Zelda's strategy to validate the efficacy of medical cannabis in key indications.

Dr Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at University of California (Los Angeles, UCLA), which is part of the prestigious UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center.

He specialises in treating children, adolescents and young adults with these aggressive cancers and runs a comprehensive and multidisciplinary program involving paediatric and medical oncologists, radiation oncologists, orthopaedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists.

Registered Office:
Level 45, 108 St George's Terrace
Perth WA 6000

Postal Address:
PO Box 7315
Perth WA 6850

T: +61 8 9486 7066 F: +61 8 9486 8066

Dr Federman is also highly experienced in clinical trials and leads a high calibre clinical research team devoted to providing access to clinical trials for children with refractory, recurrent and metastatic bone and soft tissue cancers.

As a member of the Scientific Advisory Board, Dr Federman will work alongside the Zelda team to develop rigorous clinical trials in certain cancers as part of Zelda's strategy to become a leading biotechnology company in the emerging medical cannabis sector by investing in a series of high value, low cost and short duration trials.

He joins a highly respected Scientific Advisory Board, that brings a wealth of clinical and scientific knowledge and experience to Zelda and will work alongside other leading clinical and scientific members:

- Dr Joe Goldstrich – an experienced specialist and physician with extensive knowledge in the use of medical cannabis to treat a variety of conditions
- Professor Manuel Guzman - Full Professor of Biochemistry and Molecular Biology at Madrid's Complutense University and expert on the molecular mechanisms of action and role of cannabinoids in controlling cell generation and death
- Dr Cristina Sanchez - Assistant Professor at Complutense University, Madrid Spain and specialist in the area of lipid signalling, including cannabinoids in an oncology setting
- Dr Donald Abrams - a cancer and integrative medicine specialist at the UCSF Osher Center for Integrative Medicine at Mount Zion and Chief of Haematology and Oncology at San Francisco General Hospital

Commenting on the SAB appointment, Zelda Chairman Harry Karelis said:

"Dr Federman's appointment to Zelda's Scientific Advisory Board signals the strong level of medical and scientific support that the Company is experiencing for its strategy to validate the efficacy of medical cannabis in key indications. His unmatched knowledge and profile in the cancer space will be invaluable as we move forward with our research and clinical trial activities in this crucial medical area.

"Zelda is now clearly positioned as a key thought-leader globally in the medical cannabis space and with numerous governments legislating to allow medical cannabis, most recently in Australia, we are uniquely placed through our relationships to accelerate the scientific understanding and clinical benefits of medical cannabis."

Commenting on joining Zelda's SAB, Dr Noah Federman said:

"I am thrilled to be part of a team bringing a rigorous approach to evaluating the efficacy and potential benefits of medical cannabis in the treatment of cancer. I have been aware of Mara Gordon (Zelda co-founder) and her activities for some time and have witnessed first-hand the improvement in the quality of life for my patients from her deep knowledge of the biological effects of medical cannabis. Focusing on robust clinical trials to show statistically significant outcomes is crucial to validating the potential of medical cannabis to provide patients in need with new treatment options."

Dr Federman received a BA in English Literature and minor in neuroscience at Williams College, Massachusetts. He received a Medical Doctorate Degree from the Mount Sinai School of Medicine- New York University, New York and completed his residency and fellowship training in Pediatric Hematology/Oncology at the University of California, Los Angeles. He is now a full-time member of the faculty at UCLA.

ENDS



For more information:

Harry Karelis
Chairman
Zelda Therapeutics Pty Ltd
M: +61 413 056 328
E: hkarelis@titancapitalpartners.com.au

Matthew Wu
Media & Capital Partners
M: 0433 634 706
E: matthew.wu@mcpartners.com.au

About Zelda Therapeutics

Zelda Therapeutics is a Californian-based, Australian biotechnology company that brings together some of the world's leading researchers and clinicians active in the study and use of medicinal cannabis to treat a variety of ailments.

With an initial focus on certain cancers and skin conditions, we believe that by investing in rigorous scientific research and clinical trials we can generate significant value for all stakeholders as the world re-acquaints itself with this ancient medicine.

www.zeldatherapeutics.com